TOC | ID   

Pandemic (H1N1) 2009 influenza vaccine

Updated 2009 Sep 28 05:14 PM: topic created 2009 Sep 24
REF: http://dynaweb.ebscohost.com/Detail.aspx?id=474412&sid=dd350d47-a4ae-4fa1-9aeb-dd9689dcbe70@sessionmgr4  

Overview:

• vaccination efforts should begin as soon as vaccine is available
• key target groups to receive pandemic (H1N1) 2009 influenza vaccine include
  • pregnant women
  • people who live with or care for infants < 6 months old
  • health care and emergency medical services personnel
  • persons aged 6 months through 24 years
  • people aged 25-64 years who have medical conditions that put them at higher risk for influenza-related complications
• both live, attenuated and inactivated influenza A (H1N1) 2009 monovalent vaccine formulations will be available
• inactivated vaccine dosing
  • single 0.5 mL dose for adults and children e 10 years old
  • two 0.5 mL doses about 1 month apart for children ages 36 months to 9 years
  • two 0.25 mL doses about 1 month apart for children ages 6-36 months
• live attenuated vaccine dosing
  • single 0.2 mL dose for adults and children e 10 years old
  • two 0.2 mL doses about 1 month apart for children ages 2-9 years
  • each 0.2 mL dose given as 0.1 mL per nostril
• pandemic (H1N1) 2009 influenza vaccine does not replace need for seasonal influenza vaccine
• simultaneous administration of inactivated seasonal and pandemic influenza vaccines are permissible at different anatomic sites; simultaneous administration of live, attenuated vaccines not recommended
• efficacy
  • single dose of inactivated pandemic (H1N1) 2009 vaccine in healthy adults appears immunogenic with mostly mild adverse effects
  • single dose of inactivated pandemic (H1N1) 2009 vaccine appears immunogenic in most healthy children aged 10-17 years
• side effects expected to be similar to seasonal influenza vaccine and include mostly mild local and systemic reactions
• possibly very low risk of Guillain-Barre syndrome (GBS) after influenza vaccination

 

---

9-29-2009